

GLAXOSMITHKLINE PLC
Form 6-K
April 15, 2013

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending April 2013

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

Notification of Transactions of Directors, Persons Discharging

Managerial Responsibility or Connected Persons

The Administrators of the GlaxoSmithKline 2009 Deferred Annual Bonus Plan (the Plan) notified the Company and the under-mentioned persons on 15 April 2013 of the following increases in their notional interests in Ordinary Shares and American Depositary Shares (ADSs) at a price of 1549.50 pence per Ordinary Share and \$47.75 per ADS following the re-investment of dividends paid to shareholders on 11 April 2013.

Sir Andrew Witty Acquisition of 1,224 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 1,224 Ordinary Shares under the matching element of the Plan (Company contribution).

Mr S Dingemans Acquisition of 431 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 431 Ordinary Shares under the matching element of the Plan (Company contribution).

Mr S M Bicknell Acquisition of 250 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 250 Ordinary Shares under the matching element of the Plan (Company contribution).

Mrs D P Connelly Acquisition of 144 ADSs under the personal contribution element of the Plan.

Acquisition of 144 ADSs under the matching element of the Plan (Company contribution).

Mr W C Louv Acquisition of 74 ADSs under the personal contribution element of the Plan.

Acquisition of 74 ADSs under the matching element of the Plan (Company contribution).

Mr D S Redfern Acquisition of 301 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 301 Ordinary Shares under the matching element of the Plan (Company contribution).

Dr M M Slaoui Acquisition of 588 ADSs under the personal contribution element of the Plan.

Acquisition of 588 ADSs under the matching element of the Plan (Company contribution).

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Ms C Thomas Acquisition of 252 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 252 Ordinary Shares under the matching element of the Plan (Company contribution).

Mr D E Troy Acquisition of 301 ADSs under the personal contribution element of the Plan.

Acquisition of 301 ADSs under the matching element of the Plan (Company contribution).

Dr P J T Vallance Acquisition of 547 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 547 Ordinary Shares under the matching element of the Plan (Company contribution).

Ms E Walmsley Acquisition of 156 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 156 Ordinary Shares under the matching element of the Plan (Company contribution).

The notional dividends accrued will be paid out in proportion to the percentage of the participant's deferred annual bonus holdings that will vest following the end of the relevant three year measurement period.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte
Company Secretary

15 April' 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: April 15, 2013

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc